GlassScriptPhysician profile
George Stewart
NPI 1275538795
$14,692.87
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $6,448 · 2021: $6,242 · 2022: $1,342 · 2023: $59.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,941.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $735.32 | 2019-2022 | |
| Genzyme Corporation | $425.29 | 2020-2022 | |
| Covis Pharma Gmbh | $301.06 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $246.31 | 2019-2023 | |
| Grifols USA, LLC | $148.22 | 2020-2021 | |
| Pfizer INC. | $104.71 | 2019-2022 | |
| Optinose US, INC. | $84.35 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $83.36 | 2019 | |
| Csl Behring | $78.80 | 2022 | |
| Aimmune Therapeutics, INC. | $65.55 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.04 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $43.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.43 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.93 | 2023 | Rinvoq |
| Pharming Healthcare, INC. | $33.09 | 2021-2022 | |
| Uswm, LLC | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.